Newsroom | 90807 results

Lausanne, Suíça--(BUSINESS WIRE)--A Debiopharm (www.debiopharm.com), empresa biofarmacêutica suíça de capital privado dedicada ao desenvolvimento de terapias inovadoras que aumentem a qualidade de vida dos pacientes, anunciou hoje a conclusão bem-sucedida do recrutamento de pacientes em seu estudo clínico de fase III, aberto, de grupo único e multicêntrico (NCT06129539), denominado estudo LIBELULA™. O estudo avalia a eficácia, segurança e farmacocinética do Debio 4326 em pacientes pediátricos c...

ノースカロライナ州ローリー--(BUSINESS WIRE)--（ビジネスワイヤ） -- 世界最大の医療美容専門企業であるメルツ・エステティックス（Merz Aesthetics）は、米国食品医薬品局（FDA）が「ウルセラピー・プライム（Ultherapy PRIME）」を上腕前部、上腕後部および腹部の皮膚のたるみ改善に対して認可したことを発表しました。 ウルセラピー・プライムは、顔**、首、デコルテに加え、今回新たに身体*にも対応する、リアルタイム可視化機能を備えた唯一のFDA認可済みソリューションです。1これらの新たな適応は、まず米国で発売され、その後、世界各国の市場へと展開される予定です。 「今回のFDA認可は、昨年のウルセラピー・プライムの成功に続く、当社の著しい成長の証しです」と、メルツ・エステティックスの最高経営責任者（CEO）ボブ・ラティガンは述べています。「顔**から身体*へと治療領域を拡大することで、新たな施術の可能性を広げ、高まる患者ニーズに応えるとともに、非侵襲的スキンリフティングおよび引き締め分野におけるリーダーシップをさらに強化しています。」 ウルセラピー・...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with i...

GOLDEN, Colo. & CAIRO--(BUSINESS WIRE)--This partnership with EVA Pharma represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region....

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the “Program”). “We believe Niagen Bioscience is an excellent investment and the Program is a compelling u...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for safe, effective and easy-to-use on-demand treatments, presented at the American College of Alle...

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices....

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting....

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide names John Capicchioni as SVP, Commercial, Early Phase to lead business development and commercial activities for the Early Phase unit....